Screening for comorbid conditions in patients enrolled in the SODA registry: a 2-year observational analysis

Whitney W. Woodmansee, Murray B. Gordon, Mark E. Molitch, Adriana G. Ioachimescu, Don W. Carver, Beloo Mirakhur, David Cox, Roberto Salvatori

Research output: Contribution to journalArticle

Abstract

Purpose: This 2-year analysis assessed frequency of comorbidities and comorbidity screening in the Somatuline® (lanreotide, LAN) Depot for Acromegaly (SODA) registry. Methods: Patient data collected included pituitary hormone deficiencies, sleep studies, echocardiograms, gallbladder sonographies, colonoscopies, and glycated hemoglobin (HbA1c) levels. Insulin-like growth factor-1 (IGF-1) and growth hormone levels in patients with (DM) and without (non-DM) diabetes mellitus were analyzed. Results: There were 241 patients enrolled. Pituitary hormone deficiencies were reported more frequently at enrollment in male (56.9%) vs female patients (32.0%; p < 0.001). TSH deficiency was the most common endocrine deficiency (69.8%), followed by gonadotropin deficiency (62.3%). Screening tests reported at enrollment: sleep studies in 29.9% (79.2% had sleep apnea), echocardiogram in 46.1% (46.8% abnormal), gallbladder sonography in 18.7% (17.8% had gallstones), and colonoscopy in 48.1% (35.3% had polyps). Follow-up studies were reported less frequently at 1 and 2 years. HbA1c data were reported in 30.8% and 41.2% after 1 and 2 years. HbA1c levels were similar at 1 and 2 years of LAN therapy among DM and non-DM patients with available data. Fewer DM vs non-DM patients achieved IGF-1 below upper limit of normal at Month 24 (58.3% vs 80.6%; p = 0.033). Conclusions: Fewer than half of patients in SODA had screening results reported at enrollment for sleep apnea, cardiomyopathy, and colon polyps. Gallbladder imaging was reported in a minority of patients. Lower IGF-1 control rates were observed in DM vs non-DM patients at Month 24. These data suggest a need for better monitoring of comorbidities in US acromegaly patients.

Original languageEnglish (US)
Pages (from-to)1-13
Number of pages13
JournalEndocrine
DOIs
StateAccepted/In press - May 16 2018

Fingerprint

Registries
Somatomedins
Gallbladder
Comorbidity
Acromegaly
Pituitary Hormones
Sleep Apnea Syndromes
Colonoscopy
Polyps
Ultrasonography
Sleep
Glycosylated Hemoglobin A
Gallstones
Hypothyroidism
Gonadotropins
Cardiomyopathies
Growth Hormone
Diabetes Mellitus
Colon

Keywords

  • Acromegaly
  • Comorbidities
  • Extended-Release
  • Lanreotide Depot/Autogel
  • Observational Study
  • Registry

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Woodmansee, W. W., Gordon, M. B., Molitch, M. E., Ioachimescu, A. G., Carver, D. W., Mirakhur, B., ... Salvatori, R. (Accepted/In press). Screening for comorbid conditions in patients enrolled in the SODA registry: a 2-year observational analysis. Endocrine, 1-13. https://doi.org/10.1007/s12020-018-1615-3

Screening for comorbid conditions in patients enrolled in the SODA registry : a 2-year observational analysis. / Woodmansee, Whitney W.; Gordon, Murray B.; Molitch, Mark E.; Ioachimescu, Adriana G.; Carver, Don W.; Mirakhur, Beloo; Cox, David; Salvatori, Roberto.

In: Endocrine, 16.05.2018, p. 1-13.

Research output: Contribution to journalArticle

Woodmansee, Whitney W. ; Gordon, Murray B. ; Molitch, Mark E. ; Ioachimescu, Adriana G. ; Carver, Don W. ; Mirakhur, Beloo ; Cox, David ; Salvatori, Roberto. / Screening for comorbid conditions in patients enrolled in the SODA registry : a 2-year observational analysis. In: Endocrine. 2018 ; pp. 1-13.
@article{a36287393e9440ab8f470f47835769bd,
title = "Screening for comorbid conditions in patients enrolled in the SODA registry: a 2-year observational analysis",
abstract = "Purpose: This 2-year analysis assessed frequency of comorbidities and comorbidity screening in the Somatuline{\circledR} (lanreotide, LAN) Depot for Acromegaly (SODA) registry. Methods: Patient data collected included pituitary hormone deficiencies, sleep studies, echocardiograms, gallbladder sonographies, colonoscopies, and glycated hemoglobin (HbA1c) levels. Insulin-like growth factor-1 (IGF-1) and growth hormone levels in patients with (DM) and without (non-DM) diabetes mellitus were analyzed. Results: There were 241 patients enrolled. Pituitary hormone deficiencies were reported more frequently at enrollment in male (56.9{\%}) vs female patients (32.0{\%}; p < 0.001). TSH deficiency was the most common endocrine deficiency (69.8{\%}), followed by gonadotropin deficiency (62.3{\%}). Screening tests reported at enrollment: sleep studies in 29.9{\%} (79.2{\%} had sleep apnea), echocardiogram in 46.1{\%} (46.8{\%} abnormal), gallbladder sonography in 18.7{\%} (17.8{\%} had gallstones), and colonoscopy in 48.1{\%} (35.3{\%} had polyps). Follow-up studies were reported less frequently at 1 and 2 years. HbA1c data were reported in 30.8{\%} and 41.2{\%} after 1 and 2 years. HbA1c levels were similar at 1 and 2 years of LAN therapy among DM and non-DM patients with available data. Fewer DM vs non-DM patients achieved IGF-1 below upper limit of normal at Month 24 (58.3{\%} vs 80.6{\%}; p = 0.033). Conclusions: Fewer than half of patients in SODA had screening results reported at enrollment for sleep apnea, cardiomyopathy, and colon polyps. Gallbladder imaging was reported in a minority of patients. Lower IGF-1 control rates were observed in DM vs non-DM patients at Month 24. These data suggest a need for better monitoring of comorbidities in US acromegaly patients.",
keywords = "Acromegaly, Comorbidities, Extended-Release, Lanreotide Depot/Autogel, Observational Study, Registry",
author = "Woodmansee, {Whitney W.} and Gordon, {Murray B.} and Molitch, {Mark E.} and Ioachimescu, {Adriana G.} and Carver, {Don W.} and Beloo Mirakhur and David Cox and Roberto Salvatori",
year = "2018",
month = "5",
day = "16",
doi = "10.1007/s12020-018-1615-3",
language = "English (US)",
pages = "1--13",
journal = "Endocrine",
issn = "1355-008X",
publisher = "Humana Press",

}

TY - JOUR

T1 - Screening for comorbid conditions in patients enrolled in the SODA registry

T2 - a 2-year observational analysis

AU - Woodmansee, Whitney W.

AU - Gordon, Murray B.

AU - Molitch, Mark E.

AU - Ioachimescu, Adriana G.

AU - Carver, Don W.

AU - Mirakhur, Beloo

AU - Cox, David

AU - Salvatori, Roberto

PY - 2018/5/16

Y1 - 2018/5/16

N2 - Purpose: This 2-year analysis assessed frequency of comorbidities and comorbidity screening in the Somatuline® (lanreotide, LAN) Depot for Acromegaly (SODA) registry. Methods: Patient data collected included pituitary hormone deficiencies, sleep studies, echocardiograms, gallbladder sonographies, colonoscopies, and glycated hemoglobin (HbA1c) levels. Insulin-like growth factor-1 (IGF-1) and growth hormone levels in patients with (DM) and without (non-DM) diabetes mellitus were analyzed. Results: There were 241 patients enrolled. Pituitary hormone deficiencies were reported more frequently at enrollment in male (56.9%) vs female patients (32.0%; p < 0.001). TSH deficiency was the most common endocrine deficiency (69.8%), followed by gonadotropin deficiency (62.3%). Screening tests reported at enrollment: sleep studies in 29.9% (79.2% had sleep apnea), echocardiogram in 46.1% (46.8% abnormal), gallbladder sonography in 18.7% (17.8% had gallstones), and colonoscopy in 48.1% (35.3% had polyps). Follow-up studies were reported less frequently at 1 and 2 years. HbA1c data were reported in 30.8% and 41.2% after 1 and 2 years. HbA1c levels were similar at 1 and 2 years of LAN therapy among DM and non-DM patients with available data. Fewer DM vs non-DM patients achieved IGF-1 below upper limit of normal at Month 24 (58.3% vs 80.6%; p = 0.033). Conclusions: Fewer than half of patients in SODA had screening results reported at enrollment for sleep apnea, cardiomyopathy, and colon polyps. Gallbladder imaging was reported in a minority of patients. Lower IGF-1 control rates were observed in DM vs non-DM patients at Month 24. These data suggest a need for better monitoring of comorbidities in US acromegaly patients.

AB - Purpose: This 2-year analysis assessed frequency of comorbidities and comorbidity screening in the Somatuline® (lanreotide, LAN) Depot for Acromegaly (SODA) registry. Methods: Patient data collected included pituitary hormone deficiencies, sleep studies, echocardiograms, gallbladder sonographies, colonoscopies, and glycated hemoglobin (HbA1c) levels. Insulin-like growth factor-1 (IGF-1) and growth hormone levels in patients with (DM) and without (non-DM) diabetes mellitus were analyzed. Results: There were 241 patients enrolled. Pituitary hormone deficiencies were reported more frequently at enrollment in male (56.9%) vs female patients (32.0%; p < 0.001). TSH deficiency was the most common endocrine deficiency (69.8%), followed by gonadotropin deficiency (62.3%). Screening tests reported at enrollment: sleep studies in 29.9% (79.2% had sleep apnea), echocardiogram in 46.1% (46.8% abnormal), gallbladder sonography in 18.7% (17.8% had gallstones), and colonoscopy in 48.1% (35.3% had polyps). Follow-up studies were reported less frequently at 1 and 2 years. HbA1c data were reported in 30.8% and 41.2% after 1 and 2 years. HbA1c levels were similar at 1 and 2 years of LAN therapy among DM and non-DM patients with available data. Fewer DM vs non-DM patients achieved IGF-1 below upper limit of normal at Month 24 (58.3% vs 80.6%; p = 0.033). Conclusions: Fewer than half of patients in SODA had screening results reported at enrollment for sleep apnea, cardiomyopathy, and colon polyps. Gallbladder imaging was reported in a minority of patients. Lower IGF-1 control rates were observed in DM vs non-DM patients at Month 24. These data suggest a need for better monitoring of comorbidities in US acromegaly patients.

KW - Acromegaly

KW - Comorbidities

KW - Extended-Release

KW - Lanreotide Depot/Autogel

KW - Observational Study

KW - Registry

UR - http://www.scopus.com/inward/record.url?scp=85047163537&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047163537&partnerID=8YFLogxK

U2 - 10.1007/s12020-018-1615-3

DO - 10.1007/s12020-018-1615-3

M3 - Article

C2 - 29767287

AN - SCOPUS:85047163537

SP - 1

EP - 13

JO - Endocrine

JF - Endocrine

SN - 1355-008X

ER -